NCT06778187View on ClinicalTrials.gov

Oral-ATO for TP53-mutated Myeloid Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 7, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 29, 2028

Conditions
Acute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic LeukemiaTP53 Gene MutationArsenic Trioxide
Interventions
DRUG

Oral arsenic trioxide

"Patients will be treated in 28-day cycles.~Each cycles will comprise:~Oral arsenic trixoide (10mg/day or 0.15mg/kg/day in patients \< 50kg) from Days 1-14~PLUS:~* Oral ascorbic acid (1000mg/day) from Days 1-14~* Azacitidine (75mg/m2/day s.c. or i.v.) from days 1-7; OR Decitabine (20mg/m2/day i.v.) from days 1-5; OR Oral-decitabine-cedazuridine (1 tablet/day) from days 1-5.~* Venetoclax (100mg-400mg/day) from Days 1-14 (if used)"

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER